Company profile

Ticker
PKI
Exchange
CEO
Prahlad Ramadhar Singh
Employees
Incorporated
Location
Fiscal year end
Former names
EG&G INC
SEC CIK
IRS number
42052042

PKI stock data

(
)

Calendar

10 Nov 20
3 Dec 20
29 Dec 20

News

Quarter (USD) Oct 20 Jul 20 Apr 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Jan 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Perkinelmer earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
6 Nov 20 Okun Andrew Common Stock Sell Dispose S Yes 140.14 6,107 855.83K 10,310
6 Nov 20 Okun Andrew Common Stock Option exercise Aquire M No 81.29 6,107 496.44K 16,417
6 Nov 20 Okun Andrew NQ Stock Option Common Stock Option exercise Dispose M No 81.29 6,107 496.44K 3,054
2 Oct 20 Mock James M Common Stock Sell Dispose S Yes 125.08 100 12.51K 27,218
2 Oct 20 Mock James M Common Stock Sell Dispose S Yes 124.58 4,423 551.02K 27,318
2 Oct 20 Mock James M Common Stock Sell Dispose S Yes 123.69 1,100 136.06K 31,741
31 Jul 20 Goldberg Joel S Common Stock Sell Dispose S Yes 118.34 7,451 881.75K 71,792
31 Jul 20 Goldberg Joel S Common Stock Sell Dispose S Yes 117.6 15,936 1.87M 79,243
31 Jul 20 Goldberg Joel S Common Stock Option exercise Aquire M No 43.01 23,387 1.01M 95,179
31 Jul 20 Goldberg Joel S NQ Stock Option Common Stock Option exercise Dispose M No 43.01 23,387 1.01M 0
90.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 513 455 +12.7%
Opened positions 103 79 +30.4%
Closed positions 45 39 +15.4%
Increased positions 162 166 -2.4%
Reduced positions 160 140 +14.3%
13F shares
Current Prev Q Change
Total value 1.24T 976.56B +27.2%
Total shares 100.8M 102.89M -2.0%
Total puts 88.17K 109.4K -19.4%
Total calls 402K 397.1K +1.2%
Total put/call ratio 0.2 0.3 -20.4%
Largest owners
Shares Value Change
Capital Research Global Investors 12.13M $1.52B +0.0%
Vanguard 11.98M $1.5B -2.7%
Select Equity 9.31M $1.17T -1.0%
BLK Blackrock 7.12M $893.19M -1.6%
TROW T. Rowe Price 5.57M $699.29M -42.5%
STT State Street 4.51M $566.46M -1.8%
Massachusetts Financial Services 3.8M $477.52M +5.1%
JHG Janus Henderson 3.77M $473.19M -42.5%
Pictet Asset Management 2.7M $338.84M +7.0%
King Luther Capital Management 2.39M $300.43M -1.0%
Largest transactions
Shares Bought/sold Change
TROW T. Rowe Price 5.57M -4.12M -42.5%
JHG Janus Henderson 3.77M -2.79M -42.5%
Manufacturers Life Insurance Company, The 1.08M +964.57K +808.6%
Acadian Asset Management 767.98K +722.57K +1591.2%
GS Goldman Sachs 1.59M +514.03K +47.8%
Marshall Wace North America 414.19K +411.06K +13120.4%
Marshall Wace 454.67K +400.34K +736.9%
Vanguard 11.98M -330.17K -2.7%
Millennium Management 304.21K +294.25K +2955.0%
Aqr Capital Management 362.18K +255.5K +239.5%

Financial report summary

?
Risks
  • If the markets into which we sell our products decline or do not grow as anticipated due to a decline in general economic conditions, or there are uncertainties surrounding the approval of government or industrial funding proposals, or there are unfavorable changes in government regulations, we may see an adverse effect on the results of our business operations.
  • Our growth is subject to global economic and political conditions, and operational disruptions at our facilities.
  • If we do not introduce new products in a timely manner, we may lose market share and be unable to achieve revenue growth targets.
  • We may not be able to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses or licensed technologies into our existing businesses, or make acquired businesses or licensed technologies profitable.
  • We may not be successful in adequately protecting our intellectual property.
  • If we are unable to renew our licenses or otherwise lose our licensed rights, we may have to stop selling products or we may lose competitive advantage.
  • If we do not compete effectively, our business will be harmed.
  • Our quarterly operating results could be subject to significant fluctuation, and we may not be able to adjust our operations to effectively address changes we do not anticipate, which could increase the volatility of our stock price and potentially cause losses to our shareholders.
  • A significant disruption in third-party package delivery and import/export services, or significant increases in prices for those services, could interfere with our ability to ship products, increase our costs and lower our profitability.
  • Disruptions in the supply of raw materials, certain key components and other goods from our limited or single source suppliers could have an adverse effect on the results of our business operations, and could damage our relationships with customers.
  • The manufacture and sale of products and services may expose us to product and other liability claims for which we could have substantial liability.
  • If we fail to maintain satisfactory compliance with the regulations of the United States Food and Drug Administration and other governmental agencies in the United States and abroad, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil, criminal or monetary penalties.
  • Changes in governmental regulations may reduce demand for our products or increase our expenses.
  • The healthcare industry is highly regulated and if we fail to comply with its extensive system of laws and regulations, we could suffer fines and penalties or be required to make significant changes to our operations which could have a significant adverse effect on the results of our business operations.
  • Outbreaks of communicable diseases in various parts of China and other countries may materially and adversely affect our business, financial condition and results of operations.
  • Economic, political and other risks associated with foreign operations could adversely affect our international sales and profitability.
  • If we do not retain our key personnel, our ability to execute our business strategy will be limited.
  • If we experience a significant disruption in, or breach in security of, our information technology systems or those of our customers, suppliers or other third parties, or cybercrime, resulting in inappropriate access to or inadvertent transfer of information or assets, or if we fail to implement new systems, software and technologies successfully, our business could be adversely affected.
  • We have a substantial amount of outstanding debt, which could impact our ability to obtain future financing and limit our ability to make other expenditures in the conduct of our business.
  • Restrictions in our senior unsecured revolving credit facility and other debt instruments may limit our activities.
  • Discontinuation, reform, or replacement of LIBOR may adversely affect our variable rate debt.
  • Our results of operations will be adversely affected if we fail to realize the full value of our intangible assets.
  • Our share price will fluctuate.
  • Dividends on our common stock could be reduced or eliminated in the future.
Management Discussion
  • Revenue for fiscal year 2019 was $2,883.7 million, as compared to $2,778.0 million for fiscal year 2018, an increase of $105.7 million, or 4%, which includes an approximate 1% increase in revenue attributable to acquisitions and divestitures and a
  • 2% decrease in revenue attributable to changes in foreign exchange rates. The analysis in the remainder of this paragraph compares segment revenue for fiscal year 2019 as compared to fiscal year 2018 and includes the effect of foreign exchange rate fluctuations, and acquisitions and divestitures. The total increase in revenue reflects an increase in our Diagnostics segment revenue of $52.7 million, or 5%, due to growth in our reproductive health and immunodiagnostics businesses partially offset by unfavorable changes in foreign exchange rates. Our Discovery & Analytical Solutions segment revenue increased by $53.0 million, or 3%, due to an increase of $42.5 million from our life sciences market revenue and an increase of $10.4 million from our applied markets revenue, partially offset by unfavorable changes in foreign exchange rates. As a result of adjustments to deferred revenue related to certain acquisitions required by business combination rules, we did not recognize $0.8 million of revenue primarily related to our Diagnostics segment for each of fiscal years 2019 and 2018 that otherwise would have been recorded by the acquired businesses during each of the respective periods.
  • Cost of revenue for fiscal year 2019 was $1,487.6 million, as compared to $1,437.1 million for fiscal year 2018, an increase of approximately $50.6 million, or 4%. As a percentage of revenue, cost of revenue decreased to 51.6% in fiscal year 2019 from 51.7% in fiscal year 2018, resulting in an increase in gross margin of approximately 14 basis points to 48.4% in fiscal year 2019 from 48.3% in fiscal year 2018. Amortization of intangible assets increased and was $61.4 million for fiscal year 2019, as compared to $46.2 million for fiscal year 2018. Stock-based compensation expense was $1.6 million for fiscal year 2019, as compared to $1.5 million for fiscal year 2018. The amortization of purchase accounting adjustments to record the inventory from certain acquisitions added an incremental expense of $21.6 million for fiscal year 2019, as compared to $19.3 million for fiscal year 2018. Acquisition and divestiture-related expenses, contingent consideration and other costs were minimal for fiscal year 2019, as compared to an incremental expense of $0.1 million for fiscal year 2018. In addition to the factors noted above, the overall increase in gross margin primarily the result of mix, price and improved manufacturing and services productivity.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: appeal, Cambridge, cell, CRISPR, editing, engineering, function, gene, Horizon, Luxembourg, outcome, plc, reached, recommended, RNAi, UK, unity, wholly
Removed: achievement, conditional, isolation, Italy, strong, updated